Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 4, 2013, Pages 520-525

  Rodriguez, M ^a   Monedero, I ^a,b,c   Caminero, J A ^b,d   Encarnacion M ^a   Dominguez, Y ^a   Acosta, I ^e   Munoz E ^a   Camilo, E ^a   Martinez Selmo, S ^a   De Los Santos, S ^a   Del Granado, M ^f   Casals, M ^g,h   Cayla, J ^g   Marcelino, B ^a  

^a Dominican Republic National Tuberculosis Programme   (France)

^b MDR TB Unit   (France)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^e Comité Nacional de Evaluación TB MDR ^*  (Dominican Republic)

^f PAN AMERICAN HEALTH ORGANIZATION   (United States)

^g Centro de Investigacion   (Spain)

^h UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Dominican Republic; MDR TB; Multidrug resistant tuberculosis; Standardised treatment; TB; Tuberculosis

Indexed keywords

CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADD ON THERAPY; ADULT; AGE DISTRIBUTION; ARTICLE; BACTERIUM CULTURE; COMBINATION CHEMOTHERAPY; DOMINICAN REPUBLIC; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE PLANNING; HEALTH PROGRAM; HUMAN; LUNG CAVITATION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PERSONALIZED MEDICINE; POPULATION RESEARCH; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; SHORT COURSE THERAPY; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS CONTROL;

ADULT; ANTITUBERCULAR AGENTS; DEVELOPING COUNTRIES; DOMINICAN REPUBLIC; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HEALTH RESOURCES; HUMANS; INCIDENCE; MALE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; PROGRAM EVALUATION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84875466391     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0481     Document Type: Article

References (28)

1. World Health Organization. The WHO/International Union Against Tuberculosis and Lung Disease Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. Report no. 4. WHO Document 2008. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 200-8.
2. Caminero J A. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 2010; 14: 382-39-0.
3. Caminero J A. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006; 10: 829-83-7.
4. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 200-8.
5. Johnston J C, Shahidi N C, Sadatsafavi M, FitzGerald J M. Treatment outcomes of multidrug-reistant tuberculosis; a systematic review and meta-analysis. PLoS ONE 2009; 4: e691-4.
6. Orenstein E W, Basu S, Shah N S, et al. Treatment outcome among patients with multidrug-resistant tuberculosis; systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-16-1.
7. Goble M, Iseman M D, Madsen L A, Waite D, Ackerson L, Horsburgh C R Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-53-2.
8. Palmero D J, Ambroggi M, Brea A, et al. Treatment and followup of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina. Int J Tuberc Lung Dis 2004; 8: 778-78-4.
9. Suárez P G, Floyd K, Portocarrero J, et al. Feasibility and costeffectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359: 1980-198-9.
10. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-12-8.
11. Geerligs W A, van Altena R, de Lange W C M, van Soolingen D, van der Werf T S. Multidrug-resistant tuberculosis: longterm treatment outcome in the Netherlands. Int J Tuberc Lung Dis 2000; 4: 758-76-4.
12. Tahaoglu K, Törün T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-17-4.
13. World Health Organization. Global tuberculosis control; surveillance, planning, financing. WHO report 2009. Geneva, Switzerland. WHO/HTM/TM/2009.411. Geneva, Switzerland: WHO, 200-9.
14. Espinal M A, Báez J, Soriano G, et al. Drug-resistant tuberculosis in the Dominican Republic: results of a nationwide survey. Int J Tuberc Lung Dis 1998; 2: 490-49-8.
15. Canetti G, Rist N, Grosset J. Mesure de la sensibilité du bacille tuberculeux aux drogues antibacillaires par la méthode des proportions. Rev Tuberc Pneumol 1963; 27: 217-272. [French]
16. Caminero J A, Sotgiu G, Zumla A, Migliori G B. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-62-9.
17. Altman D G, Machin D, Bryant T N, Gardner M J. Statistics with confidence. 2nd ed. Bristol, UK: BMJ Group, 200-0.
18. Nunn A J, Phillips P P J, Mitchison D A. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis 2010; 14: 241-24-2.
19. Coker R. Should tuberculosis programmes invest in secondline treatments for multidrug-resistant tuberculosis (MDRTB)? Int J Tuberc Lung Dis 2002; 6: 649-65-0.
20. World Health Organization. Guidelines for establishing DOTSPlus projects for the management of multidrug-resistant tuberculosis (MDR-TB). WHO/CDS/TB/2000.279. Geneva, Switzerland: WHO, 200-0.
21. Nathanson E, Lambregts van Weezenbeek C, Rich M L, et al. Multidrug-resistant tuberculosis management in resourcelimited settings. Emerg Infect Dis 2006; 12: 1389-139-7.
22. World Health Organization. Multidrug and extensively drugresistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. Geneva, Switzerland: WHO, 201-0.
23. Keshavjee S, Gelmanova I Y, Farmer P E, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia; a retrospective cohort study. Lancet 2008; 372: 1403-140-9.
24. Leimane V, Riekstina V, Holtz T H, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-32-6.
25. Park S K, Kim C T, Song S D. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin. Int J Tuberc Lung Dis 1998; 2: 877-88-4.
26. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB; a systematic review by TBNET. Eur Respir J 2009; 33: 871-88-1.
27. Bloss E, Kukša L, Holtz T H, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-200-4. Int J Tuberc Lung Dis 2010; 14: 275-28-1.
28. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004; 8: 1382-138-4.